Modality
Radioligand
MOA
WEE1i
Target
PRMT5
Pathway
Sphingolipid
Endometrial CaRSVLGS
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Jan 2029
Phase 1Current
NCT08170862
2,929 pts·RSV
2018-04→2029-01·Recruiting
NCT06912054
2,219 pts·Endometrial Ca
2021-09→TBD·Recruiting
5,148 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-284w awayFast Track· Endometrial Ca
2029-01-152.8y awayInterim· RSV
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Recruit…
P1
Recruit…
Catalysts
Fast Track
2026-04-28 · 4w away
Endometrial Ca
Interim
2029-01-15 · 2.8y away
RSV
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08170862 | Phase 1 | RSV | Recruiting | 2929 | UPCR |
| NCT06912054 | Phase 1 | Endometrial Ca | Recruiting | 2219 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα |